TY - JOUR
T1 - A Keystone Gut Bacterium Christensenella minuta—A Potential Biotherapeutic Agent for Obesity and Associated Metabolic Diseases
AU - Ang, Wei Shan
AU - Law, Jodi Woan Fei
AU - Letchumanan, Vengadesh
AU - Hong, Kar Wai
AU - Wong, Sunny Hei
AU - Ab Mutalib, Nurul Syakima
AU - Chan, Kok Gan
AU - Lee, Learn Han
AU - Tan, Loh Teng Hern
N1 - Funding Information:
This work was supported by the Jeffrey Cheah School of Medicine and Health Sciences under Early Career Researcher Grant 2022 [Vote Number: ECR-000039] awarded to L.T.-H.T.
Publisher Copyright:
© 2023 by the authors.
PY - 2023/7
Y1 - 2023/7
N2 - A new next-generation probiotic, Christensenella minuta was first discovered in 2012 from healthy human stool and described under the phylum Firmicutes. C. minuta is a subdominant commensal bacterium with highly heritable properties that exhibits mutual interactions with other heritable microbiomes, and its relative abundance is positively correlated with the lean host phenotype associated with a low BMI index. It has been the subject of numerous studies, owing to its potential health benefits. This article reviews the evidence from various studies of C. minuta interventions using animal models for managing metabolic diseases, such as obesity, inflammatory bowel disease, and type 2 diabetes, characterized by gut microbiota dysbiosis and disruption of host metabolism. Notably, more studies have presented the complex interaction between C. minuta and host metabolism when it comes to metabolic health. Therefore, C. minuta could be a potential candidate for innovative microbiome-based biotherapy via fecal microbiota transplantation or oral administration. However, the detailed underlying mechanism of action requires further investigation.
AB - A new next-generation probiotic, Christensenella minuta was first discovered in 2012 from healthy human stool and described under the phylum Firmicutes. C. minuta is a subdominant commensal bacterium with highly heritable properties that exhibits mutual interactions with other heritable microbiomes, and its relative abundance is positively correlated with the lean host phenotype associated with a low BMI index. It has been the subject of numerous studies, owing to its potential health benefits. This article reviews the evidence from various studies of C. minuta interventions using animal models for managing metabolic diseases, such as obesity, inflammatory bowel disease, and type 2 diabetes, characterized by gut microbiota dysbiosis and disruption of host metabolism. Notably, more studies have presented the complex interaction between C. minuta and host metabolism when it comes to metabolic health. Therefore, C. minuta could be a potential candidate for innovative microbiome-based biotherapy via fecal microbiota transplantation or oral administration. However, the detailed underlying mechanism of action requires further investigation.
KW - Christensenella minuta
KW - inflammatory bowel disease
KW - metabolic diseases
KW - next-generation probiotic
KW - obesity
UR - http://www.scopus.com/inward/record.url?scp=85164975640&partnerID=8YFLogxK
U2 - 10.3390/foods12132485
DO - 10.3390/foods12132485
M3 - Review Article
C2 - 37444223
AN - SCOPUS:85164975640
SN - 2304-8158
VL - 12
JO - Foods
JF - Foods
IS - 13
M1 - 2485
ER -